Yamamoto N, Seto T, Nishio M, et al. - Given that erlotinib plus bevacizumab vs erlotinib monotherapy was shown to offer a statistically significant progression-free survival (PFS) benefit in chemotherapy-naïve Japanese patients with epidermal growth factor receptor mutation-positive ( EGFR+) non-small-cell lung cancer (NSCLC) in the JO25567 randomized Phase 2 study, researchers here report updated PFS as well as final overall survival (OS) data following a median observation span of 34.7 months. Participants were patients suffering from stage IIIB/IV or postoperative recurrent NSCLC. Until disease progression or unacceptable toxicity, these participants were randomly assigned to receive oral erlotinib 150 mg once daily ( n = 77) or erlotinib plus intravenous bevacizumab 15 mg/kg every 21 days ( n = 75). According to findings, experts observed that no significant improvement in OS was conferred by bevacizumab added to first-line erlotinib in Japanese patients with stage IIIB/IV or postoperative recurrent EGFR+ NSCLC. The median OS benefit (as long as 4 years) was shown to be comparable in both treatment arms, regardless of individual patient characteristics. The addition of bevacizumab to erlotinib was correlated with a significant improvement in PFS, which was consistent with the primary analysis.